Effects of ramosetron orally disintegrating tablets on the prophylaxis of post-discharge nausea and/or vomiting in female patients undergoing day surgery under general anesthesia: a randomized controlled trial

Hyun-Jung Shin, Yong-Hee Park, Minying Chang, Yun Jeong Chae, Hun-Taek Lee, Oh Haeng Lee, Sang-Kee Min, Sang-Hwan Do, Hyun-Jung Shin, Yong-Hee Park, Minying Chang, Yun Jeong Chae, Hun-Taek Lee, Oh Haeng Lee, Sang-Kee Min, Sang-Hwan Do

Abstract

Background: This study was performed to evaluate the effectiveness of ramosetron orally disintegrating tablets (ODTs) in preventing post-discharge nausea and/or vomiting (PDNV) in female patients following outpatient surgery under general anesthesia.

Methods: This multicenter randomized study included three South Korean tertiary hospitals. Before surgery, 138 patients were randomly allocated into two groups. In the ramosetron group, ramosetron ODT 0.1 mg was administered after discharge in the morning of postoperative days 1 and 2. Metoclopramide 10 mg was administered as a rescue antiemetic (capped at 30 mg per day). In the control group, patients were administered only metoclopramide 10 mg when nausea and/or vomiting occurred. The primary outcome was the incidence of nausea during 24 h after discharge.

Results: We found significant differences in the incidence (13% vs. 33%, P = 0.008) and severity (P = 0.011) of nausea between the ramosetron and the control groups during 24 h after discharge. In addition, the rate of rescue antiemetic (metoclopramide) administration during 24 h after discharge was lower in the ramosetron group (6%) than in the control group (18%) (P = 0.033). Patient satisfaction score was higher in the ramosetron group than in the control group (P < 0.001).

Conclusion: Ramosetron ODT reduces the incidence and severity of postoperative nausea after discharge during the first 24 h and may be a valuable option for the prevention of PDNV in female patients after day surgery under general anesthesia.

Trial registration: ClinicalTrials.gov, NCT04297293 . Registered on 05 March 2020.

Keywords: Nausea; Outpatient surgery; Post-discharge; Ramosetron; Vomiting.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flowchart for patient selection

References

    1. Apfel CC, Philip BK, Cakmakkaya OS, Shilling A, Shi YY, Leslie JB, et al. Who is at risk for postdischarge nausea and vomiting after ambulatory surgery? Anesthesiology. 2012;117(3):475–486. doi: 10.1097/ALN.0b013e318267ef31.
    1. Blacoe DA, Cunning E, Bell G. Paediatric day-case surgery: an audit of unplanned hospital admission Royal Hospital for Sick Children, Glasgow. Anaesthesia. 2008;63(6):610–615. doi: 10.1111/j.1365-2044.2008.05438.x.
    1. Carroll NV, Miederhoff P, Cox FM, Hirsch JD. Postoperative nausea and vomiting after-discharge from outpatient surgery centers. Anesth Analg. 1995;80(5):903–909.
    1. Gan T, Sloan F, Dear Gde L, El-Moalem HE, Lubarsky DA. How much are patients willing to pay to avoid postoperative nausea and vomiting? Anesth Analg. 2001;92(2):393–400. doi: 10.1213/00000539-200102000-00022.
    1. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118(1):85–113. doi: 10.1213/ANE.0000000000000002.
    1. Gan TJ, Franiak R, Reeves J. Ondansetron orally disintegrating tablet versus placebo for the prevention of postdischarge nausea and vomiting after ambulatory surgery. Anesth Analg. 2002;94(5):1199–1200. doi: 10.1097/00000539-200205000-00027.
    1. Gan TJ, Meyer TA, Apfel CC, Chung F, Davis PJ, Habib AS, et al. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2007;105(6):1615–1628. doi: 10.1213/01.ane.0000295230.55439.f4.
    1. Hall MJ, Schwartzman A, Zhang J, Liu X. Ambulatory surgery data from hospitals and ambulatory surgery centers: United States, 2010. Natl Health Stat Report. 2017;102:1–15.
    1. Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J Pharmacol Sci. 2007;104(3):263–273. doi: 10.1254/jphs.FP0070620.
    1. Kim D, YaDeau J, Lin Y, Gordon M, Zayas V, Rade M, et al. Antiemetic prophylaxis with ondansetron for post-discharge nausea and vomiting after hip arthroscopy performed under neuraxial anesthesia: a prospective, randomized, placebo-controlled trial. J Anesth Clin Res. 2013;4(12)
    1. Lee HJ, Kwon JY, Shin SW, Kim CH, Baek SH, Baik SW, et al. Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients. Eur J Anaesthesiol. 2008;25(9):756–762. doi: 10.1017/S0265021508004262.
    1. Melton MS, Klein SM, Gan TJ. Management of postdischarge nausea and vomiting after ambulatory surgery. Curr Opin Anaesthesiol. 2011;24(6):612–619. doi: 10.1097/ACO.0b013e32834b9468.
    1. Noda K, Ikeda M, Yoshida O, Yano S, Taguchi T, Shimoyama T, et al. Clinical evaluation of ramosetron injections in the treatment of cisplatin-induced nausea and vomiting. J Int Med Res. 2002;30(3):211–219. doi: 10.1177/147323000203000301.
    1. Pan PH, Lee SC, Harris LC. Antiemetic prophylaxis for postdischarge nausea and vomiting and impact on functional quality of living during recovery in patients with high emetic risks: a prospective, randomized, double-blind comparison of two prophylactic antiemetic regimens. Anesth Analg. 2008;107(2):429–438. doi: 10.1213/ane.0b013e318172f992.
    1. Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc) 2002;38(2):75–89. doi: 10.1358/dot.2002.38.2.820104.
    1. Roh GU, Yang SY, Shim JK, Kwak YL. Efficacy of palonosetron versus ramosetron on preventing opioid-based analgesia-related nausea and vomiting after lumbar spinal surgery: a prospective, randomized, and double-blind trial. Spine (Phila Pa 1976) 2014;39(9):E543–E549. doi: 10.1097/BRS.0000000000000236.
    1. Ryu JH, Jeon YT, Hwang JW, Oh AY, Moon JY, Ro YJ, et al. Intravenous, oral, and the combination of intravenous and oral ramosetron for the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, controlled trial. Clin Ther. 2011;33(9):1162–1172. doi: 10.1016/j.clinthera.2011.07.018.
    1. Sanmukhani JJ, Pawar P, Mittal R. Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: the Indian experience. South Asian J Cancer. 2014;3(2):132–137. doi: 10.4103/2278-330X.130466.
    1. Swaika S, Pal A, Chatterjee S, Saha D, Dawar N. Ondansetron, ramosetron, or palonosetron: which is a better choice of antiemetic to prevent postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy? Anesth Essays Res. 2011;5(2):182–6.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다